Evolution Research Group, LLC, a leading independent clinical research site business serving pharmaceutical companies and CROs, has appointed Davide Molho, D.V.M., as President and Chief Executive Officer.

Lori Thievon Wright, who held the position for the past five years and is a co-founder of the company, will transition to Chairman of the Board of Directors, where she will remain an active member.

Dr. Molho brings 25 years of experience in the pharmaceutical services industry, most recently with Charles River Laboratories, where he served as President and Chief Operating Officer.

“ERG’s customer-centric culture, extreme focus on quality and science, exceptional patient care, and high rate of employee engagement convinced me this is the right opportunity in which I can contribute to the success of clients developing new life saving drugs,” Molho said. “ERG has a solid foundation and tremendous ability to identify precisely the right patients for trials. I look forward to deepening this capability within existing therapeutic areas, expanding into new areas, and focusing on strategic growth.”

“The past five years have been incredibly rewarding and I feel so fortunate to have had some of the most talented and dedicated professionals in the industry join ERG during my tenure, culminating in Davide joining this month,” Wright said. “The success of ERG has exceeded my wildest expectations and with Davide leading the strategy, I believe there is no limit to what this team can accomplish.”

“Davide will continue the great leadership of the company as we pursue its next growth phase,” added ERG Board Member and Partner at Linden Capital Partners, Michael Farah. “We commend Lori on building a world-class and market-leading organization, thank her for her years of dedication to ERG, and look forward to her continued involvement as Chairman of the Board.”

About Evolution Research Group

Evolution Research Group, LLC is a leading independent clinical research site business serving pharmaceutical companies and CROs, with a focus in neuroscience and other special populations. The Company is comprised of 13 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites. ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, hepatic impairment, as well as normal healthy volunteers. For more information, please visit www.evolutionresearchgroup.com.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.